The Delhi High Court on Friday canceled the ban of the health ministry on the sale of oxytocin by private players that the government did not have a scientific basis to ban the drug and it did not consider the users of the drug as a threat. In a 100-page petition, Justice S. Ravindra Bhat and A. Chawla noted that both of them are inappropriate and arbitrary;The Union of India did not adequately weigh in the risks to users of oxytocin, nor generally consider potentially harmful effects to potential people of limited supply, if the construction is limited to one unit. Oxytocin is used in pregnant women to induce labor and postpartum bleeding is a major cause of maternal death. India is one of the highest rates of maternal mortality in the country.
However, after the direction of the court of Himachal Pradesh in June this year, the Health Ministry decided to ban the manufacture of this drug by private players on the ground that the drug was misused to increase milk production in cattle. In its directive, the Ministry of Health allowed only Karnataka Antibiotics Limited to make the drug under Section 26 (A) of the Drugs and Cosmetics Act (D & C). This act gives the government the power to restrict the creation of medicines and cosmetic in public interest. But drug maker PfizerNSE 0.33%, Milane's activist group All India Drugs Action Network (AIDAN) took the government to court that in order to challenge the ban, the government alleged that there was no scientific evidence to prove it That drug was harmful or misused.
Delhi HC, a potentially life-saving drug for pregnant women and young mothers, said that it is difficult to accept that oxytocin is risky for human or even animal life. Delhi HC noted that the drug is strongly recommended by the WHO at the time of childbirth, which is given injection. According to the admission of the Ministry of Health and Central Drugs Standard Control Organization (CDSCO), Oxytocin is later recognized as a medical use for the induction and promotion of labor to regulate bleeding. The court also informed that from 2012 to 2018, the Drugs Consultative Committee has consistently observed that in medicine there is "a definite role" in the medical sector for both humans and animals and such legitimate construction and sale of drugs can not be stopped.